[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sleep-apnea-syndromes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sleep-apnea-syndromes":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,38,69,94,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100376788","clinical-characteristics-of-patients-with-sleep-apnea-in-korea-100376788",false,"NCT04186078","Clinical Characteristics of Patients With Sleep Apnea in Korea","Clinical Characteristics of Patients With Sleep Apnea in Korea: a Prospective Cohort Study","Inclusion Criteria:\n\n* Participants who are suspected of sleep apnea due to symptoms such as snoring, witnessed apneas, waking up with a choking sensation, excessive sleepiness, non-restorative sleep, difficulty initiating or maintaining sleep, fatigue or tiredness, and morning headache\n\nExclusion Criteria:\n\n* None","ALL","19 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","Sleep-disordered breathing including obstructive sleep apnea (OSA) is an extremely common medical disorder associated with important morbidity. The purpose of this study is to understand the clinical features and course of patients with sleep apnea in Korea. Participants who are suspected of sleep apnea due to symptoms such as snoring, witnessed apneas, waking up with a choking sensation, excessive sleepiness, non-restorative sleep, difficulty initiating or maintaining sleep, fatigue or tiredness, and morning headache will be prospectively recruited at the outpatient clinic of Seoul National University Hospital. After polysomnography (PSG) or respiratory polygraphy, patients with sleep apnea including OSA and central sleep apnea (CSA) will be followed regularly. Participants not having sleep apnea (apnea-hypopnea index \\\u003C 5\u002Fhour) will only have a baseline visit. For only participants with the informed consent of donating blood, their blood samples will be collected and stored in the Seoul National University Hospital-Human Biobank (SNUH-HUB).",[24],"Sleep Apnea Syndromes","RECRUITING","2026-04-21",{"date":28,"type":29},"2026-04-24","ACTUAL",{"date":31,"type":29},"2019-11-11",{"date":33,"type":20},"2046-12",{"name":35,"class":36},"Seoul National University Hospital","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":37},"100468666","home-apnea-testing-in-children-trial-100468666","NCT05382754","Home Apnea Testing in CHildren Trial","Home Sleep Apnea Testing Compared to In-lab Polysomnography for the Evaluation of Obstructive Sleep Apnea in Children","HATCH","Inclusion Criteria:\n\n* Male and female children age 5-12 years old inclusive\n* Referred for diagnostic PSG at the Children's Hospital of Philadelphia (CHOP) Sleep Laboratory for evaluation of OSA as part of clinical care\n* Parental\u002Fguardian permission (informed consent) and if appropriate, child assent.\n\nExclusion Criteria:\n\n* Children without Down syndrome who have had a PSG within 3 years of enrollment\n* Children with Down syndrome who have had a PSG within 1 year of enrollment.\n* Children with a history of hypoventilation or hypoxemia or who require supplemental oxygen or positive airway pressure during sleep\n* Children with a tracheostomy or tracheocutaneous fistula\n* Children who live in a facility without their parent","5 Years","12 Years",{"count":49,"type":20},317,"INTERVENTIONAL",[52],"NA","This clinical trial will compare home sleep apnea testing with the gold standard in-lab polysomnography in terms of 1) accuracy, 2) therapeutic decision-making, and 3) parent\u002Fchild acceptability in children referred for evaluation of obstructive sleep apnea.",[55,56,24,57],"Sleep Apnea, Obstructive","Sleep Disorder","Sleep Disturbance",[59,60],"obstructive sleep apnea","home sleep apnea testing","2026-04-16",{"date":26,"type":29},{"date":64,"type":29},"2023-03-29",{"date":66,"type":20},"2027-07",{"name":68,"class":36},"Children's Hospital of Philadelphia",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":50,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":93},"100560533","efficacy-investigation-of-the-medical-device-apneal-on-smartphone-for-sleep-apnea-hypopnea-syndrome-diagnosis-100560533","NCT06578390","Efficacy Investigation of the Medical Device Apneal® on Smartphone for Sleep Apnea-Hypopnea Syndrome Diagnosis","SESAME","Inclusion Criteria:\n\n* Individuals, male or female, aged 18 years or older (no upper age limit).\n* Individuals for whom polysomnography (PSG) is indicated as part of routine care, regardless of the specific indication.\n* Individuals with a reported total sleep time of at least 6 hours, in accordance with AASM recommendations for PSG analysis.\n* Individuals affiliated with social security or benefiting from a similar system, if applicable, in accordance with local regulations.\n* Voluntary individuals who have provided oral and written consent after being informed by the research investigator.\n\nExclusion Criteria:\n\n* Individuals with an active implantable medical device (e.g., electronic cardiac implant, neurophysiological electrical stimulator).\n* Individuals with a chest deformity that prevents proper placement of the smartphone on the chest.\n* Individuals with uncontrolled psychiatric disorders that prevent them from giving full consent to the study.\n* Individuals unable to understand or speak the official language of the research center.\n* Individuals currently excluded from another protocol or participating in another interventional research study.\n* Vulnerable persons or adults under legal protection, including pregnant or breastfeeding women, persons deprived of liberty by judicial or administrative decision, individuals hospitalized without consent, or admitted for purposes other than research (Articles L1121-5 to L1121-8 of the French Public Health Code).",true,"18 Years",{"count":79,"type":20},500,[52],"The goal of this clinical trial is to evaluate the effectiveness of the Apneal® app in diagnosing sleep apnea syndrome (SAS) in adults who require polysomnography (PSG) as part of routine care. The main questions it aims to answer are:\n\n* Can Apneal® accurately classify the SAS severity into four categories (normal: AHI \\\u003C 5, mild: 5 ≤ AHI \\\u003C 15, moderate: 15 ≤ AHI \\\u003C 30, and severe: AHI ≥ 30) compared to PSG ?\n* How does Apneal® perform in estimating the Apnea-Hypopnea Index (AHI), detecting sleep stages, differentiating between central and obstructive apneas, and identifying patient movements?\n\nParticipants will:\n\n* Wear the Apneal® app-equipped smartphone and undergo PSG during a full night of sleep at home.\n* Complete several questionnaires assessing sleep symptoms and experience with the Apneal® app.",[24],"2025-09-23",{"date":85,"type":29},"2025-09-29",{"date":87,"type":29},"2024-03-26",{"date":89,"type":20},"2026-02-28",{"name":91,"class":92},"Mitral","INDUSTRY",11,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":37},"100599600","typological-study-of-sleep-pathologies-during-psoriatic-rheumatism-and-sapho-syndrome-prospective-study-within-the-paris-saint-joseph-hospital-group-100599600","NCT07086599","Typological Study of Sleep Pathologies During Psoriatic Rheumatism and SAPHO Syndrome: Prospective Study Within the Paris Saint-Joseph Hospital Group\"","SleepSO2","Inclusion Criteria:\n\n* Patient aged 18 years or older\n* Patient diagnosed with psoriatic arthritis or SAPHO syndrome and followed at Paris Saint-Joseph Hospital\n* Patient presenting sleep disorders warranting hospitalization for further -investigation of these disorders\n* French-speaking patient\n* Patient who does not oppose participation in the research protocol\n\nExclusion Criteria:\n\n* Patient already followed for a sleep disorder\n* Patient who underwent polysomnography in the last 2 years\n* End-of-life patient\n* Patient under guardianship or curatorship\n* Patient deprived of liberty\n* Patient under legal protection",{"count":102,"type":20},100,"Chronic inflammatory rheumatisms (CIR) are a source of motor disability and various comorbidities, particularly cardiovascular and metabolic. They also significantly impact patients' quality of life, including sleep disturbances. Among CIRs, psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis, typically seronegative for rheumatoid factor. This heterogeneous disease affects peripheral and\u002For axial joints and can include extra-articular manifestations such as uveitis and chronic inflammatory bowel diseases. Its prevalence is estimated between 0.3% and 1% in the general population.\n\nSAPHO syndrome, similar to psoriatic arthritis, is characterized by specific bone involvement with a hypertrophic tendency, often affecting the axial skeleton and the anterior thoracic wall. Pain and inflammation are closely linked to sleep quality, creating a vicious cycle where pain disrupts sleep and poor sleep amplifies pain perception. Analgesic treatments, such as opioids, can also cause nocturnal respiratory pathologies, further disrupting sleep.\n\nInflammatory processes are regulated by sleep, influencing plasma concentrations of CRP, IL6, and TNF production. Patients with psoriatic arthritis or SAPHO syndrome share common risk factors with Obstructive Sleep Apnea Syndrome (OSAS), such as obesity, hypertension, and metabolic syndrome.\n\nSleep disorders are common in the general population and likely underdiagnosed in these patients. Several studies suggest a link between sleep disorders and these rheumatic conditions, affecting quality of life and exacerbating symptoms. Questionnaires like the Epworth and Pichot scales provide a more precise evaluation of these symptoms. However, objective sleep exploration through polysomnography has never been conducted in these patients.\n\nIn summary, CIRs, particularly psoriatic arthritis and SAPHO syndrome, significantly impact patients' quality of life and sleep, necessitating appropriate evaluation and management of associated sleep disorders.",[105,106,24],"Psoriasis Arthritis","SAPHO Syndrome","2025-07-18",{"date":109,"type":29},"2025-07-25",{"date":111,"type":29},"2023-11-13",{"date":113,"type":20},"2027-11-01",{"name":115,"class":36},"Fondation Hôpital Saint-Joseph",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":127,"conditions":128,"keywords":133,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":37},"100393144","apnea-stroke-and-incident-cardiovascular-events-100393144","NCT04399200","Apnea, Stroke and Incident Cardiovascular Events","Sleep Apnea Syndrome and Incidence of Major Adverse Cardiac and Cerebrovascular Events (MACCEs) After a First Stroke","ASCENT","Inclusion Criteria:\n\n* Male or female, aged 18 to 85 years\n* Admitted in the stroke unit no later than 72h after the onset of stroke symptoms:\n\n  * First stroke confirmed by computed tomography scan or magnetic resonance imaging, whatever the localization\n  * Initial or recurrent TIA, as defined by a brief and sudden neurological dysfunction for which an ischemic cause is presumed, with symptoms lasting less than 24 hours, and\u002For with no visible lesion on neuroimaging evaluation.\n* Score on the Modified Ranking scale (mRS) ≤1 before stroke\n* Signed informed consent by patient or his\u002Fher relative if not able\n* Patient eligible to carotid endarterectomy (for ancillary study only)\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Past history of stroke\n* Inability to follow rehabilitation procedure\n* Patients with ongoing treatment for SDB\n* Exclusion period for another study\n* Patients not affiliated to a French social and health insurance system or equivalent\n* Prisoners or patients who require protection by the law","85 Years",{"count":126,"type":20},1620,"This prospective cohort study aims to compare the proportion of cardiac or cerebrovascular events after a first stroke, a first transient ischemic attack (TIA) or recurrent TIA, between sleep-disordered breathing (SDB) and non-SDB (control) patients, one year after SDB diagnosis, performed 3 months after stroke onset.\n\nThe primary outcome is a composite endpoint composed of cardiac or cerebrovascular events regrouping: death from any cardiac or cerebrovascular cause, non-fatal stroke, and non-fatal acute coronary disease.\n\n1620 patients, in the acute phase of a first stroke, TIA or recurrent TIA will be included in the cohort.\n\nClinical, neuroimaging, sensorimotor, cognitive and biological parameters will be collected at inclusion. Three months after stroke or TIA onset, polysomnography will be performed for SDB diagnosis. Patients will be considered as having SDB for an Apnea-Hypopnea Index (AHI) \\> 15 events\u002Fhour, or to the control group otherwise. The same clinical, imaging, cognitive and biological assessments than during the first visit will be performed; incident (new) cardiovascular events will be collected. Three months later, and at 1, 2, 3, 4 and 5 years after SDB diagnosis, the same clinical, cognitive, sensorimotor, and sleep-related evaluations will be performed. In addition to the aforementioned parameters, incident cardiovascular outcomes will be collected, at the same time points. The primary study outcome will be retrieved one year after stroke onset.",[129,130,24,55,131,132],"Stroke","Sleep-disordered Breathing","Sleep Apnea, Central","Fragmentation, Sleep",[129,130,134,135],"Cardio-Vascular Events","Atherosclerosis","2025-02-07",{"date":138,"type":29},"2025-02-11",{"date":140,"type":29},"2020-07-13",{"date":142,"type":20},"2035-06-01",{"name":144,"class":36},"University Hospital, Grenoble"]